Hepatitis B Surface Antibody

SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years.

WASHINGTON — Preliminary results showed combined VIR-2218 and VIR-3434 therapy reduced hepatitis B surface antigen with mild adverse events among a small subset of patients with chronic HBV infection.